Immune Mechanisms of Protection Against Mycobacterium tuberculosis Center (IMPAc-TB)

The Immune Mechanisms of Protection Against Mycobacterium tuberculosis Center (IMPAc-TB) program, solicited under BAA-75N93026R00008, seeks to advance tuberculosis vaccine development by defining tissue-specific and systemic immune responses that confer protection against M. tuberculosis, including in the context of HIV/SIV co-infection. The program requires integrated approaches combining human clinical samples or studies, at least one validated animal model, and computational modeling to identify immune signatures linked to disease risk or protection, evaluate protective antigens and epitopes, and refine biological models such as organoids or ex vivo systems for cross-species analysis. Proposals must not include cross-contract collaborative studies at the time of submission; however, awardees are required to reserve $300,000 annually from their individual budgets during years two through five to support future collaborative activities selected by NIH program staff, principal investigators, and the External Scientific Advisory Group. Contract performance is expected to commence on or around September 1, 2027, with a maximum duration of five years, and funding will be provided through cost reimbursement, completion-type contracts. The National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID), is the procuring agency, with an estimated annual program budget of $10.5 million, expecting to award two to three contracts each with total annual costs of approximately $5 million. All proposals must be submitted electronically through the NIAID eCPS portal at https://ecps.nih.gov/, and submissions via email, fax, or collect calls are strictly prohibited. The solicitation was posted on June 2, 2026, with a proposal deadline of September 1, 2026, and the contract is classified under NAICS code 541715 for research and development in the physical, engineering, and life sciences.